Strategic design of extracellular vesicle drug delivery systems

被引:200
作者
Armstrong, James P. K.
Stevens, Molly M. [1 ]
机构
[1] Imperial Coll London, Dept Mat, Dept Bioengn, London SW7 2AZ, England
基金
英国惠康基金;
关键词
Drug delivery; Extracellular vesicles; Exosomes; Microvesicles; Liposomes; EXOSOMES; BRAIN; BIODISTRIBUTION; CELLS; SIRNA; LIPOSOMES; INJECTION; VEHICLES; TRIAL; MICE;
D O I
10.1016/j.addr.2018.06.017
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Extracellular vesicles (EVs), sub-micron vectors used in intercellular communication, have demonstrated great promise as natural drug delivery systems. Recent reports have detailed impressive in vivo results from the administration of EVs pre-loaded with therapeutic cargo, including small molecules, nanoparticles, proteins and oligonucleotides. These results have sparked intensive research interest across a huge range of disease models. There are, however, enduring limitations that have restricted widespread clinical and pharmaceutical adoption. In this perspective, we discuss these practical and biological concerns, critically compare the relative merit of EVs and synthetic drug delivery systems, and highlight the need for a more comprehensive understanding of in vivo transport and delivery. Within this framework, we seek to establish key areas in which EVs can gain a competitive advantage in order to provide the tangible added value required for widespread translation. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:12 / 16
页数:5
相关论文
共 67 条
[1]
Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[2]
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes [J].
Alvarez-Erviti, Lydia ;
Seow, Yiqi ;
Yin, HaiFang ;
Betts, Corinne ;
Lakhal, Samira ;
Wood, Matthew J. A. .
NATURE BIOTECHNOLOGY, 2011, 29 (04) :341-U179
[3]
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics [J].
Armstrong, James P. K. ;
Holme, Margaret N. ;
Stevens, Molly M. .
ACS NANO, 2017, 11 (01) :69-83
[4]
Strategies for cell membrane functionalization [J].
Armstrong, James P. K. ;
Perriman, Adam W. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (10) :1098-1106
[5]
Targeted drug delivery to tumors: Myths, reality and possibility [J].
Bae, You Han ;
Park, Kinam .
JOURNAL OF CONTROLLED RELEASE, 2011, 153 (03) :198-205
[6]
Liposome application: problems and prospects [J].
Barenholz, Y .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2001, 6 (01) :66-77
[7]
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC [J].
Besse, Benjamin ;
Charrier, Melinda ;
Lapierre, Valerie ;
Dansin, Eric ;
Lantz, Olivier ;
Planchard, David ;
Le Chevalier, Thierry ;
Livartoski, Alain ;
Barlesik, Fabrice ;
Laplanche, Agnes ;
Ploix, Stephanie ;
Vimond, Nadege ;
Peguillet, Isabelle ;
Thery, Clotilde ;
Lacroix, Ludovic ;
Zoernig, Inka ;
Dhodapkar, Kavita ;
Dhodapkar, Madhav ;
Viaud, Sophie ;
Soria, Jean-Charles ;
Reiners, Katrin S. ;
von Strandmann, Elke Pogge ;
Vely, Frederic ;
Rusakiewicz, Sylvie ;
Eggermont, Alexander ;
Pitt, Jonathan M. ;
Zitvogel, Laurence ;
Chaput, Nathalie .
ONCOIMMUNOLOGY, 2016, 5 (04)
[8]
Emerging role of extracellular vesicles in inflammatory diseases [J].
Buzas, Edit I. ;
Gyoergy, Bence ;
Nagy, Gyoergy ;
Falus, Andras ;
Gay, Steffen .
NATURE REVIEWS RHEUMATOLOGY, 2014, 10 (06) :356-364
[9]
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59 [J].
Clayton, A ;
Harris, CL ;
Court, J ;
Mason, MD ;
Morgan, BP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (02) :522-531
[10]
PHASE-1 AND PHARMACOKINETIC TRIAL OF LIPOSOME-ENCAPSULATED DOXORUBICIN [J].
CONLEY, BA ;
EGORIN, MJ ;
WHITACRE, MY ;
CARTER, DC ;
ZUHOWSKI, EG ;
VANECHO, DA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (02) :107-112